A new trading day began on Tuesday, with Biogen Inc (NASDAQ: BIIB) stock price down -2.18% from the previous day of trading, before settling in for the closing price of $172.03. BIIB’s price has ranged from $170.71 to $268.30 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Over the past five-year period, the drop rate of yearbook sales for the company of the Healthcare sector was -4.53%. Meanwhile, its annual earnings per share averaged 11.55%. With a float of $144.59 million, this company’s outstanding shares have now reached $144.90 million.
Considering the fact that the conglomerate employs 7570 people, you should pay attention to its efficiency factor. In terms of profitability, gross margin is 71.81%, operating margin of 20.63%, and the pretax margin is 20.27%.
Biogen Inc (BIIB) Insider Activity
As we move forward, let’s examine how large-scale investors are investing in this stock of the Drug Manufacturers – General Industry. The insider ownership of Biogen Inc is 0.77%, while institutional ownership is 89.35%. The most recent insider transaction that took place on Sep 03 ’24, was worth 88,019. In this transaction Head of Development of this company sold 431 shares at a rate of $204.22, taking the stock ownership to the 5,316 shares. Before that another transaction happened on Sep 03 ’24, when Company’s Officer proposed sale 431 for $204.22, making the entire transaction worth $88,019.
Biogen Inc (BIIB) Earnings and Forecasts
In its latest quarterly report, released on 9/30/2024, the company reported earnings of 3.3 per share, which was $0.1 higher than the consensus estimate of $0.26. In terms of return on equity, this company recorded -19.55% in contrast with 50.0% return on Investment (trailing twelve months). Wall Street market experts anticipate that the next fiscal year will bring earnings of 3.92 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 11.55% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 4.86% during the next five years compared to -18.05% drop over the previous five years of trading.
Biogen Inc (NASDAQ: BIIB) Trading Performance Indicators
Here are Biogen Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 0.80. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 2.66. Likewise, its price to free cash flow for the trailing twelve months is 12.59.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 11.07, a number that is poised to hit 3.44 in the next quarter and is forecasted to reach 16.91 in one year’s time.
Technical Analysis of Biogen Inc (BIIB)
Compared to the last year’s volume of 1.16 million, its volume of 1.54 million showed improvement in the last five days. As of the previous 9 days, the stock’s Stochastic %D was 9.38%. Additionally, its Average True Range was 4.39.
During the past 100 days, Biogen Inc’s (BIIB) raw stochastic average was set at 0.81%, which indicates a significant decrease from 2.87% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 22.91% in the past 14 days, which was lower than the 24.77% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $188.32, while its 200-day Moving Average is $211.20. Nevertheless, the first resistance level for the watch stands at $170.69 in the near term. At $173.10, the stock is likely to face the second major resistance level. The third major resistance level sits at $174.59. If the price goes on to break the first support level at $166.79, it is likely to go to the next support level at $165.30. Should the price break the second support level, the third support level stands at $162.89.
Biogen Inc (NASDAQ: BIIB) Key Stats
With a market capitalization of 24.52 billion, the company has a total of 145,719K Shares Outstanding. Currently, annual sales are 9,836 M while annual income is 1,161 M. The company’s previous quarter sales were 2,466 M while its latest quarter income was 388,500 K.
